Table 1 Baseline characteristics of the study patients (N = 1023).

From: Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial

Characteristic

All patients (N = 1023)

Age, median (range), yr.

72 (60–92)

Female sex, n (%)

433 (42)

Ethnicity, n (%)

 Hispanic

23 (2)

 Non-Hispanic

951 (93)

 Unknown

49 (5)

Race, n (%)

 White

801 (78)

 African American

47 (5)

 Asian

30 (3)

 Multiple or other

78 (8)

 Unknown

67 (7)

Cytogenetics, n (%)b

 Normal karyotype

333 (36)

 Complex karyotype

280 (30)

 Chromosome 5/5q, 7 or 17 abnormalities

54 (6)

 Core-binding factor

35 (4)

 KMT2A-rearrangement

21 (2)

 inv(3) or t(3;3) or t(3q26.2;v)

15 (2)

 t(6;9)

2 (0.2)

 t(8;16)

3 (0.3)

 Other

183 (20)

Mutation, n (%)a

 IDH1/2d

282 (28)

 DNMT3A

259 (25)

 TP53

256 (25)

 TET2

241 (24)

 RUNX1

227 (22)

 SRSF2

222 (22)

 ASXL1

215 (21)

 FLT3c

210 (21)

 NPM1

207 (20)

 NRAS

175 (17)

 MLL2

146 (14)

 PTPN11

105 (10)

 STAG2

100 (10)

 BCOR

98 (10)

 CEBPA

85 (8)

 NF1

84 (8)

 U2AF1

80 (8)

 KRAS

79 (8)

 SF3B1

66 (6)

 EZH2

58 (6)

 ZRSR2

39 (4)

  1. aMutations were considered present at any detectable variant allele frequency (VAF).
  2. bCytogenetics were available for 923/1023.
  3. cFLT3 was mutated in 210 patients; 109 patients had a FLT3-ITD mutation, 65 patients had a FLT3-TKD mutation, 14 patients had both FLT3-ITD and FLT3-TKD.
  4. dIDH1/2 was mutated in 282 patients; 89 patients had an IDH1 mutation, 193 patients had an IDH2 mutation, and 10 patients had both an IDH1 and an IDH2 mutation.
Back to article page